DVLT Q1 2026 update: contract story is bigger, cash proof is still the test
A filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
24Results20Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
DVLT June 2026 deep dive: the $2B headline is not the thesis yetXORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing risk
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
DVLT June 2026 deep dive: the $2B headline is not the thesis yet
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenDVLT institutional flow check: financing signal, not a supply-crunch thesis
A source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenCRISPR Therapeutics: CASGEVY launch, pipeline proof, and binary risk
A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
OpenCRISPR Therapeutics: commercial gene editing meets binary pipeline risk
A Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
OpenAIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAII: the Florida homeowners bet now keeps more risk
American Integrity is a newly public but seasoned Florida residential property insurer. The latest filings show 437,308 policies in force, $974.8 million of in-force premium, a 75.0% Q1 combined ratio and a reduced non-catastrophe quota share that lets AII kee
OpenAHMA: profitable Dubai events operator, founder-control risk included
Ambitions is a profitable Dubai MICE and tourism services operator with $20.2 million of fiscal 2025 revenue, but the public-equity case carries newly public issuer, founder-control, internal-control, cash-conversion and listing-risk watch items.
OpenAFJK: 1.04 million public shares left to carry a $1.5 billion hydrogen deal
Aimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAFCG: the BDC conversion only matters if the cannabis workout works
Advanced Flower Capital's first quarter as a BDC showed dividend-covering NII and higher NAV, but three nonaccrual loans still represented 36.6% of amortized cost and 23.5% of fair value.
OpenAEXA: $351M in trust, no operating business, and a deadline that matters
AEXA is not a business yet. It is a NYSE-listed SPAC with $351.4 million in trust, $0.3 million of cash outside trust, no selected target as of March 31, 2026, and public shareholder economics that turn on redemption value, sponsor incentives and the future de
OpenAeva: the LiDAR design-win story racing a $35M quarterly loss
Aeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2
OpenAtlas Energy Solutions: the frac-sand company chasing a 1.4 GW power pivot
Atlas Energy Solutions still depends on Permian completions, proppant volumes and the Dune Express. The new question is whether a 1.4 GW Caterpillar framework and a 120 MW tech-customer PPA can turn AESI into a power supplier before leverage, losses and execut
OpenAES: the $15 cash deal that admits the capital problem
AES has a large clean-power and utility platform, but the March 2026 $15.00 cash merger agreement changes the public-equity question into a regulatory-close trade backed by a company-disclosed growth-capital problem.
OpenAeries Technology: the AI-services rebound with a delisting clock
Aeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
OpenAeroméxico: the Delta overhang behind a record-margin airline
Aeroméxico has premium demand, loyalty scale and record-margin evidence after its U.S. listing, but the Delta JCA, MEX constraints, fuel, FX, engine issues and a negative equity balance sheet make the setup high risk.
OpenAlliance Entertainment: the $1 billion physical-media machine betting nostalgia still ships
AENT is a profitable physical-media and collectibles distributor with more than $1 billion of annual revenue, improving margins, exclusive studio and label relationships, insider control and a balance sheet that depends on inventory, receivables and revolver a
OpenAgnico Eagle: the gold cash machine betting Detour and Finland can keep it fed
AEM just turned a high gold price into record free cash flow, a net-cash balance sheet, a bigger dividend, and 55.4 million ounces of gold reserves. The hook is what comes next: Detour Lake, Canadian Malartic/Odyssey and a Finland land grab have to keep the ou
OpenAdvanced Energy's AI power boom comes with a $1 billion zero-coupon twist
AEIS just put up 26% Q1 revenue growth, more than doubled Data Center Computing revenue, crossed a 40% non-GAAP gross-margin milestone, and priced $1.0 billion of 0% convertible notes. The upside is real; so are the customer, working-capital, and dilution ques
OpenAehr Test: AI Burn-In Orders Are Back, but the P&L Still Looks Reset
Aehr Test just printed a $37.2 million bookings quarter tied to AI processors, silicon photonics, and hyperscale data-center infrastructure. The harder part is still ahead: turning that order rebound into revenue, margin recovery, and per-share value after a w
Open